Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

MedXY Editorial Team•Jan 17, 2026•Clinical Updates

The ATTAIN-2 phase 3 trial demonstrates that orforglipron, a daily oral small-molecule GLP-1 receptor agonist, significantly reduces body weight by up to 9.6% in adults with type 2 diabetes.
The GATEWAY phase 2 trial shows zodasiran (RNAi targeting ANGPTL3) reduces LDL cholesterol by approximately 40% in patients with homozygous familial hypercholesterolaemia (HoFH).
A nationwide cohort study identifies delayed puberty in male adolescents as a significant, BMI-independent risk factor for early-adult-onset type 2 diabetes.
International consensus now strongly endorses the use of Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) for pregnant women with type 1 diabetes to optimize perinatal outcomes.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The ATTAIN-2 phase 3 trial demonstrates that orforglipron, a daily oral small-molecule GLP-1 receptor agonist, significantly reduces body weight by up to 9.6% in adults with type 2 diabetes.
The GATEWAY phase 2 trial shows zodasiran (RNAi targeting ANGPTL3) reduces LDL cholesterol by approximately 40% in patients with homozygous familial hypercholesterolaemia (HoFH).
A nationwide cohort study identifies delayed puberty in male adolescents as a significant, BMI-independent risk factor for early-adult-onset type 2 diabetes.
International consensus now strongly endorses the use of Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID) for pregnant women with type 1 diabetes to optimize perinatal outcomes.